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Abstract
Background
Tuberculosis (TB) patients face substantial delays prior to treatment initiation, and out of
pocket (OOP) expenditures often surpass the economic productivity of the household. We
evaluated the pre-diagnostic cost and health seeking behaviour of new adult pulmonary TB
patients registered at Primary Health Centres (PHCs) in Vellore district, Tamil Nadu, India.
Methods
This descriptive study, part of a randomised controlled trial conducted in three rural Tuber-
culosis Units from Dec 2012 to Dec 2015, collected data on number of health facilities, dates
of visits prior to the initiation of anti-tuberculosis treatment, and direct OOP medical costs
associated with TB diagnosis. Logistic regression analysis examined the factors associated
with delays in treatment initiation and OOP expenditures.
Results
Of 880 TB patients interviewed, 34.7% presented to public health facilities and 65% patients
sought private health facilities as their first point of care. The average monthly individual
income was $77.79 (SD 57.14). About 69% incurred some pre-treatment costs at an aver-
age of $39.74. Overall, patients experienced a median of 6 days (3–11 IQR) of time to treat-
ment initiation and 21 days (10–30 IQR) of health systems delay. Age 40 years (aOR:
1.73; CI: 1.22–2.44), diabetes (aOR: 1.63; CI: 1.08–2.44) and first visit to a private health
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facility (aOR: 17.2; CI: 11.1–26.4) were associated with higher direct OOP medical costs,
while age 40 years (aOR: 0.64; CI: 0.48–0.85) and first visit to private health facility (aOR:
1.79, CI: 1.34–2.39) were associated with health systems delay.
Conclusion
The majority of rural TB patients registering at PHCs visited private health facilities first and
incurred substantial direct OOP medical costs and delays prior to diagnosis and anti-tuber-
culosis treatment initiation. This study highlights the need for PHCs to be made as the pre-
ferred choice for first point of contact, to combat TB more efficiently.
Introduction
Tuberculosis (TB), an airborne infectious disease, is one of the leading causes of mortality in
India [1]. India is one of the 30 high burden countries for TB, TB-HIV and MDR-TB. More
than one quarter of TB cases and TB-related deaths worldwide occur in India each year, the
highest of any country [2]. The private sector is an important source of treatment of tuberculo-
sis, where 5.3 million cases received treatment in 2014 alone [3]. Lack of protocol based diag-
nostic practices in the private sector delays accurate diagnosis, and the treatment offered is
maybe substandard [4,5]. Patients are not aware of the national program [6] and meet several
health care providers before receiving the correct diagnosis and appropriate treatment regimen
[7,8]. It remains unclear to what extent these health seeking behaviours and substandard clini-
cal practices result in more advanced disease progression, increased transmission, and finan-
cial burden to the patient.
TB primarily affects the poor. Those who develop TB often experience severe economic
hardship. A study from rural India found that TB patients face substantial catastrophic costs
associated with their illness; on average, the overall costs exceeded 193% of the estimated
monthly income of a daily wage labour [9]. There is substantial evidence showing financial
burden of TB in middle and low-income countries, where the average total costs incurred for
TB treatment are equivalent to 58% of annual individual income and 39% of household
income [10]. The out of pocket expenditure for medical care far surpasses the economic pro-
ductivity of household. The World Health Organization (WHO) has set an ambitious target to
eliminate the number of TB-affected families facing catastrophic costs associated with tubercu-
losis (e.g., exceeding 20% of the household’s annual income) by 2035 [11].
The purpose of this study is to evaluate the pre-diagnostic cost and to explore the patient
health care-seeking pathways for diagnosis and treatment initiation. We describe the pathways
(i.e., number and type of health facilities visited and time taken to start with treatment initia-
tion) and direct OOP medical costs incurred prior to the initiation of anti-tuberculosis treat-
ment of new adult pulmonary TB (PTB) patients under Revised National Tuberculosis
Control Program (RNTCP) in India.
Methods
Study design and setting
The descriptive study was part of a larger randomized controlled trial (RCT) designed to test
the efficacy of TB case management by different types of community based DOT providers
from a cohort of TB patients recruited between December 2012 and December 2015. The
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study was conducted in rural areas of Vellore district, Tamil Nadu, a southern state of India.
Vellore is one of the larger districts in Tamil Nadu, where 57% of the population lives in rural
areas [12]. The public health care facilities in the district include 101 primary health centres
(PHCs), 13 secondary referral hospitals (Sub district hospitals), and one tertiary referral hospi-
tal (Government Vellore Medical College). Tuberculosis services are provided through 7
Tuberculosis Units (TUs). Apart from these, there are private health care facilities, one tertiary
care centre (Christian Medical College and Hospital), private hospitals, private practitioners,
and those practising Ayurveda, Yoga, Unani, Siddha and Homoeopathy (AYUSH) systems of
medicine.
Out of 7 TUs in Vellore district, the parent study purposively selected three peripheral TUs
(Natrampalli, Pudhupadi, and Punnai) because these are geographically distant from the ter-
tiary health care facilities and that would best reflect TB case management among the rural
population.
Study participants
Of the 1833 patients registered for DOTS in 48 PHCs during the study time period, the parent
study enrolled 1080 adult PTB cases (923 new and 157 previously treated cases) after meeting
eligibility criteria and informed consent. The study excluded patients with severe illnesses,
such as weight less than 30 kg, acute or chronic liver or kidney disease, psychiatric illness, his-
tory of default on previous DOTS based on medical record review, and non-ambulatory
patients, defined as persons not being able to go to the PHC/DOT provider’s house by usual
transport. Of the 923 new cases, we were able to identify 880 patients’ (95%) treatment path-
ways, direct OOP medical costs, and time delays information. These 880 patients were
included in the secondary analysis.
Ethics statement
The parent study, RCT has been approved by the Institutional Review Boards of Brown Uni-
versity, USA; Christian Medical College, Vellore, India; Pennsylvania State University, USA;
University of Cambridge, UK; and the National Institute for Research in Tuberculosis, Chen-
nai, India. The study was registered in Clinical Trials Registry of India (CTRI/2016/08/
007203). The present secondary analysis of data was approved by the Union Ethics Advisory
Group, Paris, France. Participation of the US Centers for Disease Control and Prevention
(CDC) in this project did not meet the definition of engagement in human subjects’ research
and hence a separate institutional review board approval was not required.
Operational terms
Pathways. Patient visits to various health facilities in a care pathway before anti-tubercu-
losis treatment initiation at DOTS centre (facility in the health system for the diagnosis and
treatment of TB under national TB control program, RNTCP) were classified in to two broad
categories: 1) Public and 2) Private (PVT). Public health care facilities were further categorized
in to: A) Primary Health Centres (PHCs), B) Public Referral Hospitals (PRHs)—including sec-
ondary and tertiary referral centres, and C) TB Sanatorium (ST), a nodal centre for TB man-
agement, situated in Tambaram, Chennai, about 120 km away from the study area. Private
health care facilities include secondary and tertiary referral centre participating in RNTCP,
non-participating allopathic clinics and practitioners (registered and unregistered) and
AYUSH practitioners.
Direct medical costs. Direct medical costs included out of pocket payment (OOP)
incurred by the patient for the diagnosis of illness in health facilities before treatment
Pre-treatment pathways and costs by new adult pulmonary TB patients
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initiation. This includes a composite cost of consultation fees, investigations (such as Haemo-
globin, Total, and differential counts, Blood sugar, Liver function test, Serum creatinine, Spu-
tum for acid fast bacilli, Chest X-ray, and additional tests such as CT-Scan) and cost of all
medicines prescribed at the time of health facility visits.
Time delays in a care pathway. The framework of time delays was adopted from a WHO
study “Diagnostic and treatment delay in tuberculosis” [13] (Fig 1). We studied two time
delays in a care pathway: 1) Health systems delay–defined as the duration from first health care
facility visit to date of anti-tuberculosis treatment initiation, and 2) Treatment delay–defined
as the duration of greater than 7 days between the date of TB diagnosis and date of anti-tuber-
culosis treatment initiation under DOTS in respective PHCs [14].
Current smoker is someone who has smoked more than 100 cigarettes or hand rolled beedis
in their lifetime and has smoked in last 28 days. Current alcohol user is someone who had a
past history of alcohol consumption and has consumed in last 28 days.
Data collection
Trained field investigators collected the data using structured questionnaire in a direct inter-
view. Interviews were conducted either by making home visits or at the health centres based
on study participants’ preference. Participants were then asked for information related to past
experiences at different health facilities, incurred direct OOP medical costs for each facility,
and the time taken to start anti-tuberculosis treatment. Further information related to the
place of diagnosis and date of treatment initiation was recorded from the TB programme regis-
ters at PHCs.
Data analysis
Data collected was double entered and analysed using STATA.13 (StataCorp College Station,
TX). Key clinical and demographic patient characteristics were summarized using means
(standard deviation, SD) and medians (inter quartile range, IQR). Direct OOP medical costs
and health systems delay were dichotomised by median cut-off values. We used univariable
analysis to describe the distribution of select risk factors (e.g., age, sex, education, employment
status, health behaviours, body mass index (BMI), and HIV infection and other comorbid con-
ditions). We used multiple logistic regression to assess factors independently associated with
the primary outcomes–median of direct OOP medical costs and health systems delay–based
on adjusted odds ratios (aOR) and corresponding 95% confidence intervals (95% CI). All
potential models were reduced using backward elimination, maintaining variables with P val-
ues<0.05.
Fig 1. Framework showing various time delays from onset of symptoms to treatment initiation. Study presented
only health system and treatment delays (Unshaded areas).
https://doi.org/10.1371/journal.pone.0191591.g001
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Economic analysis
Cost data was collected using local currency units (Indian Rupees, INR) directly reported from
participants. All local currency amounts were converted into 2017 US $ [$1.00 = 64.66 INR].
Results
Patient characteristics
Of 880 patients (685 initial sputum smear-positive and 195 sputum smear-negative), 688
(78%) were males and 192 (22%) were females, with an average age of 46.6 (SD 14.16) years.
The majority of patients (78%) did not attain a secondary level of education. Among the 696
(79%) employed population, a large proportion were daily wage earners either in agriculture
or industrial sectors. The average monthly individual income was $77.79 (SD 57.14). Of 688
males, 58 (6.5%) were smokers, 137 (15.5%) were alcohol consumers, 204 (23%) undertook
both behaviours and 481(55%) do not smoke or consume alcohol. Of 192 females, there were
two smokers, four alcohol consumers and one undertook both behaviours. The majority of
patients (69%) were underweight (BMI<18.5) at the time of treatment initiation.
Health care seeking patterns in the patient care pathway
The study recorded a maximum of four health care facility visits by patients prior to anti-
tuberculosis treatment initiation. The 880 patients’ pathways to different health care facilities
(Fig 2) were divided into 20 major care pathways (Table 1). We found that 306 (35%), 571
(65%) and 3 (0.3%) patients first sought treatment at public, private, and AYUSH health care
facilities, respectively. Of the 306 patients who sought treatment first at public health care facil-
ities, 207 (68%) started on treatment whereas of the 571 patients who went to private health
care facilities first, only 63 (11%) were started on treatment. The remaining made visits to a
myriad of other health facilities before treatment initiation. Furthermore, these patients who
visit private health facilities first were more likely to have multiple visits to other providers.
The majority of patients (91%) were diagnosed at a public health facility finally. Overall, the
largest group (55%) was diagnosed at secondary referral centres (Sub district hospitals) and
few at private health facilities (9%) or PHCs (10%) (Table 2).
Fig 2. Chord diagram showing patients’ pathways to different health facilities prior to DOTS initiation in
primary health centres under RNTCP, India. Chord diagram shows the inter-relationships between patient’s
pathways to different health facilities in order of I/ II/ III/ IV towards DOTS, the volume at each facility is presented in
numbers and the matrix with different colours indicates the pathway relationship. Interactive link https://app.powerbi.
com/view?r=eyJrIjoiM2FjNzJiMmUtNDVjNy00YTNkLTgwZjMtNGQzOTI0NzYwOTk0IiwidCI6IjdlNzgyYTc2LWU
zZTQtNDQ1Ny04YzQzLWQ1NDVjNmRkYjUwZSJ9.
https://doi.org/10.1371/journal.pone.0191591.g002
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Direct out of pocket medical expenditure in stages of patient care pathways
The median/IQR of out of pocket payments per patient was $7.75 ($0.00 –$23.20), with a
mean of $27.30. About one third (31%) of patients did not incur any pre-treatment costs. Of
the 69% who incurred pre-treatment costs, the average amount spent was $39.74. The average
cost for patients who visited private health care facilities first was $38.78. When we compared
Table 1. Pathways, pre-diagnosis direct OOP medical costs, and health systems delay among new adult pulmo-
nary TB patients registered for DOTS in rural PHCs, Vellore district, India.
Pathways n % Direct OOP medical costs in
US $
Median (IQR)
Health systems delay (in
days)
Median (IQR)
First health visit in PHC to DOTS
PHC 21 2.4 0.00 10 (7–21)
PHC! PRH 34 3.9 0.00 14 (8–30)
PHC! ST 10 1.1 0.00 28 (17–52)
PHC! PVT 4 0.5 7.70 (4.20–39) 16 (15–20)
PHC! PVT! PRH/ST 7 0.8 31 (17–93) 20 (17–31)
Total first visit in PHC 76 8.7 0.00 17 (10–30)
First health visit in PRH to DOTS
PRH 162 18.4 0.00 14 (7–30)
PRH! ST 12 1.4 0 (0–0.50) 30 (22–67)
PRH! PVT 16 1.8 23 (12–71) 25 (12–30)
PRH! PVT! PRH/ST 9 1.0 8.30 (7.70–12.40) 18 (14–30)
Total first visit in PRH 199 22.6 0.00 14 (7–30)
First health visit in ST to DOTS
ST 24 2.7 0.00 30 (13–30)
ST! PRH 6 0.7 0.00 33 (14–60)
ST! PVT! PRH 1 0.1 15.50 18
Total first visit in ST 31 3.5 0.00 30 (14–30)
First health visit in PVT to DOTS
PVT 63 7.2 12.40 (5.80–31) 14 (7–30)
PVT! PRH 268 30.5 9.30 (4.40–18.60) 21 (14–30)
PVT! ST 70 8.0 11.60 (6.30–26) 30 (14–36)
PVT! PVT 60 6.8 43.80 (15.50–77.50) 30 (14–30)
PVT! PHC! PRH 17 1.9 7.70 (6.20–46.50) 20 (10–30)
PVT! PVT! PRH 76 8.6 31 (15.50–59.60) 30 (15–45)
PVT! PVT! PVT! PRH 17 1.9 77.50 (44–248) 30 (14–60)
Total first visit in PVT 571 65 13 (6.20–38.70) 25 (14–30)
First health visit in AYUSH to DOTS
AYUSH 3 0.3 31 (15.50–38.70) 30 (22–45)
First health visit in Public / Private health system / AYUSH to DOTS
First visit in Public health sector (PHC
+PRH+ST)
306 34.7 0.00 15 (7–30)
First visit in Private health sector (PVT) 571 65 13 (6.20–38.70) 25 (14–30)
First visit in AYUSH 3 0.3 31 (15.50–38.70) 30 (22–45)
Overall 880 100 7.75 (0–23.20) 21 (10–30)
PHC–Private Health Centres, PRH–Public Referral Hospitals (secondary and tertiary referral centres), ST–
Sanatorium, PVT–Private health facilities, AYUSH—Ayurveda, Yoga, Unani, Siddha and Homoeopathy systems of
medicine
https://doi.org/10.1371/journal.pone.0191591.t001
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the costs incurred by patients who visited private and public health sectors, patients who vis-
ited private health facilities first spent more: Median(IQR) $13.00 ($6.20 –$38.70) vs. $0.00
($0.00 - $0.00) in public health facilities (Table 1).
Heath systems delay and treatment delay in a patient care pathway
The median number of days taken for initiation of anti-tuberculosis treatment from the day of
first visit to a health facility (health systems delay) was 21 days (10–30 IQR) (Table 1). The
minimum and maximum days taken for initiation of anti-TB treatment was 1 and 365 days.
The median and interquartile range values for health systems delay in various facilities were 17
days (10–30 IQR) at PHCs, 14 days (7–30 IQR) at PRHs, 30 days (14–30 IQR) at the TB Sana-
torium and 25 days (14–30 IQR) days at PVT health facilities. Very few patients, 3 (0.3%), vis-
ited AYUSH practitioners, and the median days to initiation of treatment was 30 days (22–45
IQR).
We observed a time lag between the point of diagnosis of illness and treatment initiation
was a median of 6 days (3–11 IQR). After diagnosis of illness, 38 (4%) patients were started on
treatment on the day of diagnosis, 511 (58%) patients were started treatment between one to
seven days and 331 (38%) patients started treatment after seven days (our definition of treat-
ment delay). The majority of patients 486 (55%) were diagnosed at secondary referral hospitals
and had a median of 5 days (2–8 IQR) duration between point of diagnosis of illness and treat-
ment initiation. Of the 149 (17%) patients diagnosed at TB Sanatorium, 109 (73%) experienced
a median treatment delay of 15 days (11–22 IQR) (Table 2).
Direct OOP medical costs that exceeded the median were associated with age ( 40 years),
secondary level of education, current employment, non-smoking status at time of treatment
initiation, diabetes, low BMI, and first visit to a private health facility in a care pathway. After
adjusting for the above in logistic regression analysis, age ( 40 years), diabetes, and first visit
to private health facility were significantly associated with higher pre-treatment OOP cost
(Table 3).
Longer health system delays (above median 21 days) were associated with age (> 40 years),
diabetes, and those who first visited private health facility in a care pathway. After adjusting
for the above in logistic regression analysis, age (> 40 years) and first visit to private health
facility were significantly associated with health system delay (Table 4). There were no
Table 2. Place of TB diagnosis and time taken for treatment initiation after diagnosis (treatment delay, if > 7 days).
Place of TB diagnosis N (%) Time taken for treatment initiation Median (IQR) in days Treatment delay
Median (IQR) in days
Treatment delay (>7 days)
n (%)
Primary health centres (PHC) 88 (10) 5 (2–9) 14 (9–20) 33 (38)
Public secondary referral centresa 486 (55) 5 (2–8) 12 (9–18) 125 (26)
Public tertiary referral centresb 78 (9) 6 (4–10) 11 (9–16) 28 (36)
Private hospitals/clinicsc 30 (3) 4 (2–14) 17 (14–32) 11 (37)
Private tertiary referral centresb 49 (6) 8 (4–12) 12 (9–18) 25 (51)
TB Sanatoriumd 149 (17) 12 (7–19) 15 (11–22) 109 (73)
Total 880 6 (3–11) 13 (10–20) 331 (38)
aPublic secondary referral centres include all the sub district hospitals in the study area.
bTertiary referral centres include the medical colleges where patients were diagnosed and referred to DOTS centre
cPrivate hospitals/clinics include secondary hospitals and private practitioners in the study area
dTB Sanatorium is a higher centre for the TB management, the observed delay in treatment initiation was due to delay in transit from TB sanatorium to the respective
PHCs for registration under DOTS.
https://doi.org/10.1371/journal.pone.0191591.t002
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associations between gender, occupation, initial smear status, current smoker, and alcohol
consumption with health system delays and incurred direct OOP medical costs in patient care
pathways.
Discussion
The Government of India’s National Strategic Plan (NSP 2017–2025) aims to achieve “zero”
catastrophic cost for TB patients by 2020 and the elimination of TB by 2025 through an inte-
grated four-strategies approach: “Detect–Treat–Prevent–Build” (DTPB) [15]. Our study
highlighted the patients’ treatment pathways and burden of direct OOP medical costs prior to
DOTS initiation under the national TB control program (RNTCP) in India. The study exclu-
sively examined a rural population where health care seeking is onerous compared to urban
Table 3. Factors associated with high direct out of pocket medical costs (above median 7.75 US $) in a patient care pathway by univariable and multivariable
analysis.
Characteristics n High direct OOP medical costs, n (%) Unadjusted odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Sex
Male (R) 688 307 (77)
Female 192 94 (23) 1.19 (0.86–1.63) ——
Age, years
>40 (R) 566 239 (60)
 40 314 162 (40) 1.45 (1.10–1.92) 1.73 (1.22–2.44)
Education
Less than secondary (R) 685 300 (75)
Secondary and above 189 99 (25) 1.41 (1.02–1.95) 1.19 (0.79–1.79)
Employment status
Non–working (R) 184 72 (18)
Working 696 329 (82) 1.39 (1.00–1.94) 1.39 (0.94–2.06)
Current smoker
Yes 265 107 (27) 0.73 (0.55–0.99) 0.83 (0.57–1.20)
No (R) 615 294 (73)
Current alcohol user
Yes 346 156 (39) 0.96 (0.73–1.27) ——
No (R) 534 245 (61)
HIV–TB
Yes 32 14 (6) 1.36 (0.67–2.77) ——
No (R) 848 239 (94)
Diabetes
Yes 176 104 (26) 1.97 (1.41–2.76) 1.63 (1.08–2.44)
No (R) 704 297 (74)
BMI
Underweight (R) 597 251 (65)
Normal & above 266 137 (35) 1.46 (1.09–1.95) 1.30 (0.90–1.86)
Form of TB
Pulmonary smear positive (R) 685 305 (78)
Pulmonary smear negative 179 88 (22) 1.20 (0.86–1.67) ——
First health care facility visit
Public (R) 307 29 (7)
Private 573 372 (93) 17.7 (11.6–26.9) 17.2 (11.1–26.4)
https://doi.org/10.1371/journal.pone.0191591.t003
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areas. We found that two thirds of patients registered under DOTS in PHCs had visited private
health care facilities first and their OOP (direct medical) payments were 17 times higher and
their health system delays were 1.8 times more likely to be long (above the median 21 days)
than the patients who first approached the public health system.
A study by Rajeswari et al, conducted before the large-scale implementation of DOTS in
Tamil Nadu, reported that 54%, 27% and 19% of TB patients first consulted private practition-
ers, public health systems and others, respectively, for their TB diagnosis and treatment [7]. A
contemporary qualitative study by Sudha et al conducted in southern India found that private
practitioners were the first and preferred point of contact for 57% of urban and 47% of the
rural populations, and the major reasons quoted were the good quality of care and proximity
of a health facility to the residence [16]. After implementation of DOTS, studies from southern
India by Selvam et al and Charles et al reported 47% and 61% of TB patients in rural areas
Table 4. Factors associated with health systems delay (above median 21 days) in a patient care pathway by univariable and multivariable analysis.
Characteristics n Health systems delay, n (%) Unadjusted odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Sex
Male (R) 688 305 (77)
Female 192 93 (23) 1.15 (0.83–1.58) ——
Age, years
>40 (R) 566 276 (69)
 40 314 122 (31) 0.65 (0.49–0.86) 0.64 (0.48–0.85)
Education
Less than secondary (R) 685 319 (80)
Secondary and above 189 76 (20) 0.76 (0.54–1.05) ——-
Employment status
Non–working (R) 184 72 (18)
Working 696 329 (82) 1.33 (0.95–1.86) ——-
Current smoker
Yes 265 124 (31) 1.10 (0.82–1.47) ——
No (R) 615 274 (69)
Current alcohol user
Yes 346 166 (42) 1.22 (0.92–1.60) ——
No (R) 534 232 (58)
HIV–TB
Yes 32 11 (4) 0.96 (0.47–1.98) ——
No (R) 848 270 (96)
Diabetes
Yes 176 94 (24) 1.50 (1.07–2.09) 1.26 (0.89–1.78)
No (R) 704 304 (76)
BMI
Underweight (R) 597 262 (68)
Normal & above 266 126 (32) 1.15 (0.86–1.54) ——
Form of TB
Pulmonary smear positive (R) 685 303 (78)
Pulmonary smear negative 179 87 (22) 1.21 (0.87–1.69) ——
First health care facility visit
Public (R) 307 110 (28)
Private 573 288 (72) 1.77 (1.33–2.36) 1.79 (1.34–2.39)
https://doi.org/10.1371/journal.pone.0191591.t004
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sought first treatment at public health facilities, respectively [8] [17]. In contrast, after a decade
of DOTS in Tamil Nadu, our study documented that only 35% of rural TB patients first sought
treatment in the public health system. This observed difference could be due to purposive
selection of study TUs by the parent study, varying programmatic conditions, or sample selec-
tion (our sample consisted of TB patients eventually treated in the public health system). How-
ever, studies done in other regions of India have reported lower proportion of TB patients
visiting public health system first (Karnataka (16%) and rural Maharashtra (19%)) [18,19].
The private sector in India treats a large number of TB patients; as many as 5 million
patients were treated in 2014 alone [3]. This supports the view that, despite substantial plan-
ning, investment, and implementation of the TB program through the public health system,
the private sector continues to attract a large proportion of TB patients [20]. Moreover, the
quality of TB care offered by private practitioners is questionable. A recent systematic review
on quality of TB care in India finds suboptimal care [5].
Regarding the pre-treatment economic burden to the patient, several studies have reported
that the majority of costs were incurred during pre-diagnosis and the intensive phase of treat-
ment—the most critical stages of a TB episode [21,22]. We observed that 69% of patients
enrolled in the study who underwent treatment under public health system, incurred some
direct OOP medical costs during pre-treatment. On an average, these patients spent 2570 INR
($39.74), half the average monthly individual income. Substantial OOP direct medical costs
were incurred by patients who first approached private health facilities for the diagnosis of ill-
ness compared to those who presented directly to the public health system, where median
costs were zero. Despite the availability of free TB diagnostic services under the public health
system, most patients chose a private provider first resulting in substantial spending for diag-
nosis and treatment [23], which imposes an economic burden to the patient’s household [9].
Time delays occur at every point along the complex health care pathways followed by TB
patients for diagnosis and treatment [24]. Similar to previous studies [7,25,26], we found that
patients who initiated treatment in the private sector had a higher number of health facility vis-
its compared to those who first visited public health facilities. Patients who visited private
health care facilities initially also had longer health system delays: a median of 25 days (14–30
IQR) compared to 15 days (7–30 IQR) of health system delay for those who began in public
health facilities. A greater proportion of delays occurred among the patients who visited the
TB sanatorium—a median of 30 days (14–30 IQR) of health system delay and 15 days (11–22
IQR) of treatment delay. The sanatorium is a higher centre for the TB management and the
delays should be negligible. The lengthy treatment delay could be due to the transit time
needed to reach the respective PHCs for DOTS registration. Though the patients were imme-
diately started on anti-tuberculosis treatment at the sanatorium, they are directed to register at
their respective PHCs to continue the treatment. Our study considered the date of registration
in DOTS centre at respective PHCs as the date of initiation of treatment, since the drug
box was issued in the name of patient on this date.
We observed a median health system delay of 21 days (10–30 IQR) and the maximum was
365 days. The magnitude of health systems delay observed in other studies in different settings
in India ranged from a median of 13 to 54 days [18,19,27,28] and a median of 5 to 22 days in
other countries [29–31]. Delays in treatment initiation further increase the probability of TB
transmission in the community and amongst health professionals. The observed differences
across studies could be due to heterogeneity in definitions of delays (several studies define first
health care visit to date of diagnosis as health systems delay, whereas other studies consider the
time to the treatment initiation), complexity in study settings [25], or differences in treatment
procedures at health facilities.
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In the study we observed only few private hospitals/clinics were linked to DOTS program
under RNTCP and so the contribution was made least (i.e., only 3%) for the diagnosis of TB
from these centres.
Engagement of private practitioners in the functional referral system into the national pro-
gram in India must be a priority to shorten delays and reduce the financial burden on families
suffering from TB. A recent initiative in Chennai under the non-governmental organization
Resource Group for Education and Advocacy for Community Health (REACH), along with
the local health body and the National Institute for Research in Tuberculosis (NIRT), engaged
more than 600 local private practitioners to participate in the RNCTP [32]. The scaling up of a
public private mix (PPM) model has also occurred in 14 major cities of India [33] and resulted
in early suspicion of illness and referral, reduced cost and increased participation in the
RNTCP [4,34].
The REACH model identifies the potential private hospitals/clinics and provides a training
program to the medical doctor and laboratory technician according to the RNTCP protocol.
The model also offers a diagnostic and treatment facilities for the patients who are identified in
these PPM centres. It also engages local community volunteer to provide support during anti-
tuberculosis treatment. REACH also undertakes a monitoring and evaluation process along
with the RNTCP staff to ensure the accountability of the system [32].
Our study has some limitations. The sample is restricted to those who registered at govern-
ment primary health centres, which could limit the generalizability of the finding to other set-
tings, both government and private. As this was a secondary analysis, we were limited to the
data previously collected; factors such as pre-diagnostic travel and accompanying personal
costs were not available. While the interviews of patients occurred shortly after TB diagnosis,
recall bias may have resulted, especially for details related to costs incurred and exact dates of
health visits.
Conclusion
Despite more than a decade of DOTS implementation in the state of Tamil Nadu, we found a
larger proportion of rural TB patients in the study site visited private sector practitioners prior
to DOTS under RNTCP than visited public health facilities. Also, our data show that patients
who first sought care in the private sector incurred higher pre-treatment OOP direct medical
costs and longer health system delays than those who first sought care at public facilities. Our
study findings are relevant in the context of India’s Strategic Plan 2017–2025 to integrate pri-
vate provider engagement and thereby reduce catastrophic costs and time delays for TB
patients.
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